Amgen Inc. company and executive profile by Barron's. View the latest AMGN company infomation and executive bios.

Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

Patent claims reciting compounds where at least one group of a compound genus is defined by its function are common. For ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Fifth Third Wealth Advisors increased its stake in Amgen by 36.3% in Q1, now holding shares worth $1.93 million.

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Vantage Wealth bulked up its portfolio by increasing its stake in Amgen by 4.2%, now holding over $21.6 million in shares.

Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...